口服艾司氯胺酮治疗难治性抑郁:双盲随机对照试验及开放标签扩展
约三分之一抑郁症患者对现有治疗反应不足;静脉和鼻内氯胺酮/艾司氯胺酮有抗抑郁作用但可及性受限。本研究在难治性抑郁(TRD)患者中开展随机安慰剂对照试验:111名参与者先接受6周固定低剂量口服艾司氯胺酮30 mg或安慰剂每日三次,经4周洗脱后可选6周开放标签个体化滴定0.5-3.0 mg/kg每周两次。固定低剂量组与安慰剂组HDRS17总分变化无显著差异(p=0.626);开放标签滴定阶段HDRS17均值从21.0(SD 5.09)降至15.1(SD 7.27),平均差-6.0(95%CI -7.71至-4.29,p<0.001)。结果提示固定低剂量口服艾司氯胺酮对TRD无效,而个体化滴定的较高剂量可能具有抗抑郁特性。
要点
- 固定低剂量口服艾司氯胺酮30 mg每日三次对TRD的HDRS17总分改善不优于安慰剂(p=0.626)。
- 开放标签个体化滴定0.5-3.0 mg/kg每周两次阶段,HDRS17均值下降6.0分(95%CI -7.71至-4.29,p<0.001)。
- 安全性方面除头晕和睡眠幻觉评分在艾司氯胺酮组更高外,其余安全性和耐受性指标无显著差异。
核心结论
- 固定低剂量口服艾司氯胺酮对难治性抑郁无效。
- 个体化滴定的较高剂量口服艾司氯胺酮可能具有抗抑郁特性。
研究设计与样本
- 随机双盲安慰剂对照试验,含开放标签扩展,共111名难治性抑郁参与者。
- 试验分三阶段:6周固定低剂量治疗(口服艾司氯胺酮30 mg或安慰剂每日三次)、4周洗脱、可选6周开放标签个体化滴定(0.5-3.0 mg/kg每周两次)。
主要发现
- 固定低剂量阶段,艾司氯胺酮组与安慰剂组HDRS17总分从基线至6周的变化无显著差异(p=0.626)。
- 开放标签滴定阶段,HDRS17均值从21.0(SD 5.09)降至15.1(SD 7.27),平均差-6.0(95%CI -7.71至-4.29,p<0.001)。
- 安全性方面,除头晕和睡眠幻觉评分在艾司氯胺酮组更高外,其余安全性和耐受性指标无显著差异。
临床怎么用
- 固定低剂量口服艾司氯胺酮方案不推荐用于难治性抑郁的常规治疗。
- 个体化滴定的较高剂量口服艾司氯胺酮可能作为难治性抑郁的潜在治疗选择,但需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
About one-third of patients with depression do not achieve adequate response to current treatment options. Although intravenous and intranasal administrations of (es)ketamine have shown antidepressant properties, their accessibility and scalability are limited. We investigated the efficacy, safety, and tolerability of generic oral esketamine in patients with treatment-resistant depression (TRD) in a randomized placebo-controlled trial with open-label extension. This study consisted of 1) a six-week fixed low-dose treatment phase during which 111 participants received oral esketamine 30 mg or placebo three times a day; 2) a four-week wash-out phase; and 3) an optional six-week open-label individually titrated treatment phase during which participants received 0.5 to 3.0 mg/kg oral esketamine two times a week. The primary outcome measure was change in depressive symptom severity, assessed with the Hamilton Depression Rating Scale (HDRS17), from baseline to 6 weeks. Fixed low-dose oral esketamine when compared to placebo had no benefit on the HDRS17 total score (p = 0.626). Except for dizziness and sleep hallucinations scores, which were higher in the esketamine arm, we found no significant difference in safety and tolerability aspects. During the open-label individually titrated treatment phase, the mean HDRS17 score decreased from 21.0 (SD 5.09) to 15.1 (SD 7.27) (mean difference -6.0, 95% CI -7.71 to -4.29, p < 0.001). Our results suggest that fixed low-dose esketamine is not effective in TRD. In contrast, individually titrated higher doses of oral esketamine might have antidepressant properties.
引用
- Smith-Apeldoorn SY, Veraart JKE, Kamphuis J, et al. Oral esketamine in patients with treatment-resistant depression: a double-blind, randomized, placebo-controlled trial with open-label extension. Mol Psychiatry. 2024. PMID: 38523183. doi:10.1038/s41380-024-02478-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。